Beneficial effects of statins on the kidney: The evidence moves from mouse to man

Nephrology Dialysis Transplantation

Volumn 19, Issue 5, 2004, Pages 1032-1036

  Afzali, Behdad ^a   Haydar, Ali A ^a   Vinen, Katie ^a   Goldsmith, David J A ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Cholesterol; Chronic renal failure; Glomerulosclerosis; Progression; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N(G) METHYLARGININE; NITROPRUSSIDE SODIUM; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CREATININE CLEARANCE; DRUG EFFICACY; DYSLIPIDEMIA; EDITORIAL; GENDER; GLOMERULUS FILTRATION RATE; HEART PROTECTION; HUMAN; KIDNEY FUNCTION; MICROALBUMINURIA; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; SMOKING;

ANIMALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MICE; MODELS, ANIMAL;

EID: 2442526521     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh105     Document Type: Editorial

References (31)

1. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278-285
2. Taal MW, Brenner BM. Evolving strategies for renoprotection: non-diabetic chronic renal disease. Curr Opin Nephrol Hypertens 2001; 10: 523-531
3. Mann, JFE Should the results of the HOPE study affect nephrological practice? Nephrol Dial Transplant 2000; 15: 453-454
4. Hebert LA, Wilmer WA, Falkenhain ME et al. Renoprotection: one or many therapies? Kidney Int 2001; 59: 1211-1226
5. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int Suppl 1999; 71: S2-S5
6. Buemi M, Senatore M, Corica F et al. Statins and progressive renal disease. Med Res Rev 2002; 22: 76-84
7. Kasiske BL, Crosson JT. Renal disease in patients with massive obesity. Arch Intern Med 1986; 146: 1105-1109
8. Manttari M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidaemia on the decline in renal function. Hypertension 1995; 26: 670-675
9. Schaeffner ES, Kurth T, Curhan GC et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084-2091
10. Bianchi S, Bigazzi R, Caiazza A et al. A controlled prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003; 41: 565-570
11. Kano K, Nishikura K, Yamada Y, Arisaka O. Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria. Clin Nephrol 2003; 60: 85-89
12. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-269
13. Konstadinidou I, Boletis JN, Perrea D et al. Beneficial effects of fluvastatin on progressive renal allograft dysfunction. Transplant Proc 2003; 35: 1364-1367
14. Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024-2031
15. Kosch M, Barenbrock M, Suwelack B et al. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. Am J Kidney Dis 2003; 41: 1088-1096
16. van Dijk MA, Kamper AM, van Veen S, Souverijn JH, Blauw GJ. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001; 16: 2152-2157
17. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003; 138: 98-104
18. Tonelli M. Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14: 1605-1613
19. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
20. Collins R. Armitage J. Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016
21. Athyros VG, Papageorgiou AA, Mercouris BR et al, Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002: 18: 220-228
22. Athyros VG, Mikhailidis DP, Papageorgiou AA et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. J Clin Pathol 2004; in press
23. Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149-1158
24. Qin J, Zhang Z, Liu J et al. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int 2003; 64: 565-571
25. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BC et al. Controlling the epidemic of cardiovascular disease in chronic renal failure: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 32: 853-906
26. Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 2001; 12: 1549-1557
27. Harris KP, Wheeler DC, Chong CC. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int 2002; 61: 1469-1474
28. Stuveling EM, Hillege HL, Bakker SJ et al. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 2003; 63: 654-661
29. Fellstrom BC, Holdaas H, Jardine AG. Why do we need a statin trial in hemodialysis patients? Kidney Int Suppl 2003; S204-S206
30. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002; 61: 1887-1893
31. Seliger SL, Weiss NS, Gillen DL et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; 61: 297-304